ClinicalTrials.gov
public full text
Public Domain
Study of JS001 in Patients With Advanced Neuroendocrine Tumors
This is a multi-center, open-label, phase Ib study evaluating safety and efficacy of the humanized anti-PD-1 antibody JS001, as a monotherapy in patients with neuroendocrine tumors who have failed in previous systemic treatment. 40 patients are enrolled and injected with the humanized anti-PD-1 antibody 3mg/mg every 2 weeks until disease progresses or unacceptable toxicity.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors#1087322
- Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours#1085611
- Lu-177-[DOTA0,Tyr3] Octreotate Therapy in Patients With Disseminated Neuroendocrine Tumors: Analysis of Dosimetry With Impact on Future Therapeutic Strategy#178006
- TAEST16001 in the Treatment of Soft Tissue Sarcoma#898938
- AK112 Combination Therapy as First Line Treatment for Metastatic Digestive System Neuroendocrine Cancer#1113708
Record · ID 981584
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive